CareTalk: Healthcare. Unfiltered. Will Trump's Plan Cut Drug Prices?
Jun 27, 2025
The discussion centers on Trump's plan to tie U.S. drug prices to those in Europe, highlighting the potential benefits and challenges. Consumers in America face staggering drug costs, often leading to unfilled prescriptions. The debate critiques the pharmaceutical industry's profits and pushes for equitable pricing. They analyze how most favored nation pricing could reshape the landscape and tackle issues within Medicare and Medicaid systems, questioning the fairness of current pricing structures while advocating for much-needed reforms.
AI Snips
Chapters
Transcript
Episode notes
Explaining Most Favored Nation Policy
- The Most Favored Nation (MFN) policy would limit U.S. drug prices to the lowest average prices paid by major industrial countries.
- This could reduce U.S. drug costs by 50 to 90 percent, addressing affordability issues for many consumers.
U.S. Pays More Due To Lack Of Negotiation
- U.S. drug prices are significantly higher because the government historically refuses to negotiate prices with pharma.
- Other rich countries pay less and consume more because they negotiate drug prices effectively.
Pharma Raises Prices Despite Public Funding
- U.S. taxpayers heavily fund drug research but pharma still raises drug prices monthly.
- This lack of price control overcharges consumers, worsening affordability even with insurance.